Aemetis (NASDAQ:AMTX) Stock Price Passes Above 50-Day Moving Average - Here's Why

Key Points

• Aemetis stock moved above its 50-day moving average, trading as high as $3.22 and last at $2.93 on volume of about 999,902 shares versus a 50-day MA of $2.03.
• Analyst coverage is mixed with a consensus rating of "Hold" (two Buys, one Sell) and a consensus price target of $8.25, though individual views vary (e.g., Weiss Ratings "sell", Loop Capital $1.75).
• The company beat quarterly EPS estimates (−$0.24 vs. −$0.28) but missed revenue expectations ($43.31M vs. $72.07M), has a market cap of roughly $195M and a negative PE of −2.20, with analysts forecasting −2.07 EPS for the year.

Aemetis, Inc (NASDAQ:AMTX - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.03 and traded as high as $3.22. Aemetis shares last traded at $2.93, with a volume of 999,902 shares.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Aemetis in a research report on Wednesday, January 21st. Wall Street Zen upgraded Aemetis from a "sell" rating to a "hold" rating in a research report on Sunday, March 22nd. Finally, Loop Capital set a $1.75 price target on Aemetis in a research report on Thursday, March 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $8.25.

Aemetis Stock Down 5.8%

The firm has a 50-day moving average of $2.03 and a two-hundred day moving average of $1.97. The company has a market capitalization of $195.23 million, a PE ratio of -2.20 and a beta of 1.48.

Aemetis (NASDAQ:AMTX - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The specialty chemicals company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.04. The company had revenue of $43.31 million for the quarter, compared to analysts' expectations of $72.07 million. Equities analysts predict that Aemetis, Inc will post -2.07 EPS for the current fiscal year.

Institutional Trading of Aemetis

Institutional investors and hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Aemetis in the third quarter valued at approximately $86,000. Quadrature Capital Ltd purchased a new stake in shares of Aemetis in the fourth quarter valued at approximately $77,000. Jump Financial LLC purchased a new stake in shares of Aemetis in the second quarter valued at approximately $64,000. Tower Research Capital LLC TRC increased its position in shares of Aemetis by 206.7% in the second quarter. Tower Research Capital LLC TRC now owns 22,962 shares of the specialty chemicals company's stock valued at $57,000 after buying an additional 15,474 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Aemetis in the fourth quarter valued at approximately $52,000. 27.02% of the stock is currently owned by hedge funds and other institutional investors.

About Aemetis

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.